The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
V Devonshire, Y Lapierre, R Macdonell, C Ramo-Tello, F Patti, P Fontoura, L Suchet, R Hyde, I Balla, EM Frohman, BC Kieseier
EUROPEAN JOURNAL OF NEUROLOGY | WILEY | Published : 2011
BACKGROUND: most disease-modifying therapies (DMTs) for multiple sclerosis (MS) are self-injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy. This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing-remitting MS. METHODS: this was an observational, multicenter, multinational, phase 4 study. Patients and physicians received paper questionnaires regarding adherence to DMTs approved at the time of the study, including intramuscular interferon beta-1a (IFNβ-1a), subcut..View full abstract
The authors thank Orchid Jahanshahi (employed by Biogen Idec at the time the manuscript was written) for her assistance in the design of the GAP study. Editorial and formatting assistance for the manuscript was provided by Scientific Connexions, Newtown, PA, USA. This assistance was funded by Biogen Idec.This study was supported by a grant from Biogen Idec International GmbH. Statistical analyses were performed by PharmaStats (CRO Ltd) in conjunction with Biogen Idec statisticians.Dr Devonshire has received consulting fees from Bayer, Biogen Idec, Serono, and Teva Neuroscience. Dr Lapierre has served on advisory boards for Bayer, Biogen Idec, and Teva Neuroscience. Prof Macdonell has served on advisory boards for Biogen Idec, Novartis, Sanofi-Aventis, and Merck-Serono. Dr Ramo-Tello has received consulting fees from Bayer and Biogen Idec. Dr Patti has no significant relationships to disclose regarding the current study; however, he has received honoraria from Bayer-Schering, Dompe Biotec, Merck-Serono, and Sanofi-Aventis. Dr Fontoura has received speaking honoraria, grants, and travel support from Bayer-Schering, Biogen Idec, Merck-Serono, and Sanofi-Aventis; Dr Fontoura is currently an employee of F. Hoffmann-La Roche. Dr Suchet has received research support and speaker fees for meetings from Biogen Idec. Dr Hyde is an employee of Biogen Idec International GmbH. Mr Balla was an employee of Biogen Idec International GmbH at the time the study was conducted. Dr Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis, and Teva Neuroscience. Dr Frohman has served on speakers bureaus for Biogen Idec, Serono, and Teva Neuroscience.